TY - JOUR
T1 - A global approach to long-term follow-up of targeted and immune-based therapy in childhood and adolescence
AU - ACCELERATE Long-Term Follow-Up Working Group
AU - Kieran, Mark W.
AU - Caron, Hubert
AU - Winther, Jeanette Falck
AU - Henderson, Tara O.
AU - Haupt, Riccardo
AU - Hjorth, Lars
AU - Hudson, Melissa M.
AU - Kremer, Leontien C. M.
AU - van der Pal, Helena J.
AU - Pearson, Andrew D. J.
AU - Pereira, Leonardo
AU - Reaman, Gregory
AU - Skinner, Roderick
AU - Vassal, Gilles
AU - Weiner, Susan L.
AU - Horton Taylor, Danielle
N1 - Publisher Copyright: © 2021 Wiley Periodicals LLC
PY - 2021/7
Y1 - 2021/7
N2 - While considerable efforts and progress in our understanding of the long-term toxicities of surgery, radiation and chemotherapy in children with cancer have been made over the last 5 decades, there continues to be a wide gap in our knowledge of the long-term health impact of most novel targeted and immunotherapy agents. To address this gap, ACCELERATE, a multi-stakeholder collaboration of clinical and translational academics, regulators from the EMA and FDA, patient/family advocates and members spanning small biotechnology through to large pharmaceutical companies have initiated the development of an international long-term follow-up data registry to collect this important information prospectively. Providing critical safety data on the long-term use of these approved and investigational therapies in children will support the regulatory requirements and labeling information. It will also provide the necessary insight to help guide physicians and families on the appropriateness of a targeted or immune therapy for their child and inform survivorship planning.
AB - While considerable efforts and progress in our understanding of the long-term toxicities of surgery, radiation and chemotherapy in children with cancer have been made over the last 5 decades, there continues to be a wide gap in our knowledge of the long-term health impact of most novel targeted and immunotherapy agents. To address this gap, ACCELERATE, a multi-stakeholder collaboration of clinical and translational academics, regulators from the EMA and FDA, patient/family advocates and members spanning small biotechnology through to large pharmaceutical companies have initiated the development of an international long-term follow-up data registry to collect this important information prospectively. Providing critical safety data on the long-term use of these approved and investigational therapies in children will support the regulatory requirements and labeling information. It will also provide the necessary insight to help guide physicians and families on the appropriateness of a targeted or immune therapy for their child and inform survivorship planning.
KW - Childhood cancer
KW - Immunotherapy
KW - Long-term follow-up
KW - Long-term survivor
KW - Pediatric cancer
KW - Targeted therapy
KW - survivorship
UR - http://www.scopus.com/inward/record.url?scp=85104429487&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/pbc.29047
DO - https://doi.org/10.1002/pbc.29047
M3 - Comment/Letter to the editor
C2 - 33860611
SN - 1545-5009
VL - 68
JO - Pediatric blood & cancer
JF - Pediatric blood & cancer
IS - 7
M1 - e29047
ER -